Axtria White Paper

White Paper


Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in generic-to-branded drug switch-backs for some patients.  This paper also demonstrates another application of longitudinal prescription patient-level data to show how brand-to-generic substitution (especially therapeutic substitution) may produce unintended effects that are in not the best interest for some patients as measured by the rate of generic-to-branded drug switch-backs.

Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.

Fill in your details to get a copy of this whitepaper, and contact us at for any questions.

Get Your Copy!

Suggested Blogs

Let Us Show You What Axtria’s 

Solutions Can Do For You